PhotoMedex Seeks FDA OK of Laser for Atopic Dermatitis

RADNOR, Pa., May 18 -- PhotoMedex Inc. has submitted an application for 510 (k) clearance from the US Food and Drug Administration to commercially market its XTRAC laser system for the treatment of Atopic Dermatitis. Atopic Dermatitis, commonly known as eczema, is a chronic inflammation of the skin that can afflict persons of any age, but is considered to be the most common skin condition in children under the age of 11.





LATEST NEWS

• Exail Signs LLNL Contract, Partners with Eelume
  Apr 26, 2024
• Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
  Apr 26, 2024
• Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
  Apr 25, 2024
• DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
  Apr 25, 2024
• Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
  Apr 24, 2024
• One-Step Hologram Generation Speeds 3D Display Creation
  Apr 24, 2024
• Innovation Award Winners for Laser Technology Honored in Aachen
  Apr 23, 2024
• Intech 2024: AI Arrives on the Shop Floor
  Apr 22, 2024